Tomoya Kurokawa

Chiba, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Journal: BMJ open

Published: June 02, 2026

Rising Incidence With Modest Survival Improvement in Salivary Duct Carcinoma: A Population-Based Study in the United States, 2000-2022.

Rising Incidence With Modest Survival Improvement in Salivary Duct Carcinoma: A Population-Based Study in the United States, 2000-2022.

Journal: Head & neck

Published: April 16, 2026

Real-world clinical practice and economic burden of seasonal allergic rhinitis in Japan: A nationwide claims database study.

Real-world clinical practice and economic burden of seasonal allergic rhinitis in Japan: A nationwide claims database study.

Journal: Allergology international : official journal of the Japanese Society of Allergology

Published: April 03, 2026

Repression of ROBO1 Enhances Cisplatin Sensitivity in Hypermethylated Subtype of HPV-Positive Head and Neck Carcinoma.

Repression of ROBO1 Enhances Cisplatin Sensitivity in Hypermethylated Subtype of HPV-Positive Head and Neck Carcinoma.

Journal: Cancer science

Published: December 31, 2025

A phase II investigator-initiated, continuation trial of 5-aminolevulinic acid hydrochloride/sodium ferrous citrate (5-ALA-HCl/SFC) for patients with adult-onset Still's disease (AOSD) refractory to glucocorticoids.

A phase II investigator-initiated, continuation trial of 5-aminolevulinic acid hydrochloride/sodium ferrous citrate (5-ALA-HCl/SFC) for patients with adult-onset Still's disease (AOSD) refractory to glucocorticoids.

Journal: Drug discoveries & therapeutics

Published: December 10, 2025

Granulocyte-macrophage colony-stimulating factor-containing medium for blastocyst recovery culture: study protocol for a randomized controlled trial (GSET-study).

Granulocyte-macrophage colony-stimulating factor-containing medium for blastocyst recovery culture: study protocol for a randomized controlled trial (GSET-study).

Journal: Trials

Published: October 14, 2025

A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.

A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.

Journal: PloS one

Published: September 19, 2025

Efficacy of Potassium-Competitive Acid Blockers to Treat Chronic Cough Associated With "Proven" Laryngopharyngeal Reflux Disease: A Preliminary Study.

Efficacy of Potassium-Competitive Acid Blockers to Treat Chronic Cough Associated With "Proven" Laryngopharyngeal Reflux Disease: A Preliminary Study.

Journal: Cureus

Published: September 19, 2025

A Phase-II Investigator-Initiated Randomized, Double-Blind, Parallel-Group Clinical Trial of 5-Aminolevulinic Acid Hydrochloride/Sodium Ferrous Citrate (5-ALA-HCl/SFC) for Patients With Adult-Onset Still's Disease (AOSD) Refractory to Corticosteroids.

A Phase-II Investigator-Initiated Randomized, Double-Blind, Parallel-Group Clinical Trial of 5-Aminolevulinic Acid Hydrochloride/Sodium Ferrous Citrate (5-ALA-HCl/SFC) for Patients With Adult-Onset Still's Disease (AOSD) Refractory to Corticosteroids.

Journal: Cureus

Published: August 17, 2025

Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial.

Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial.

Journal: Nature communications

Published: July 01, 2025

MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial.

MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial.

Journal: JHEP reports : innovation in hepatology

Published: June 13, 2025

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results.

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results.

Journal: International journal of molecular sciences

Published: May 28, 2023

Showing 1-12 of 32

Last Updated: 09/26/2026